Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-117B in Primary Open Angle Glaucoma or Ocular Hypertension in China
NCT06666855Phase 3Active, not recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of omidenepag isopropyl in primary open-angle glaucoma (POAG) and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Intraocular Pressure at 4 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
omidenepag isopropyl
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT06666855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666855.